Safety and Effectiveness of Cinnomer^® on Disease Characteristics, Depression, and Quality of Life of Patients with Multiple Sclerosis: A Phase IV, Post-marketing, Prospective, Multicenter Study.

ABSTRACT:

Background

Every patient diagnosed with definite multiple sclerosis (MS) should begin disease modifying therapies. Cinnomer^® contains 40 mg glatiramer acetate (GA) and is available in prefilled syringes and autoinjector devices.

Methods

A phase IV multicenter study was conducted to explore the safety and effectiveness of Cinnomer^® in the treatment of MS. Study-related data were collected for 14 months.

Results

Totally, 368 Iranian relapsing-remitting MS patients in nine cities were enrolled. The patients were either treatment naïve (n=191) or switchers (n=177). Cinnomer^® treatment was associated with a significant reduction in annual relapse rate (ARR) (RR: 0.65, 95% CI: 0.43, 0.98). Final mean Expanded Disability Status Scale (EDSS) s

SUBMITTER: Naser Moghadasi A 

PROVIDER: S-EPMC10864943 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature